Navigation Links
New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs
Date:5/18/2011

WASHINGTON, May 18, 2011 /PRNewswire/ -- Ten percent of cancer patients failed to fill their initial prescriptions for oral anti-cancer drugs, according to a new study published jointly today in the Journal of Oncology Practice (JOP) and American Journal of Managed Care (AJMC). The study was based on an analysis conducted by Avalere Health LLC using pharmacy transaction data over a two-year period from 2007 to 2009. This study has also been accepted for presentation at the American Society of Clinical Oncology annual meeting on June 6th (abstract number 82120).

The study, "Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions," finds that patients were primarily abandoning their anti-cancer drugs due to two key factors: high cost-sharing and higher prescription activity. For example, claims with cost-sharing over $500 were four times more likely to be abandoned than claims with cost-sharing of $100 or less. Across the sample of prescription claims studied, Medicare coverage and lower income were also related to higher rates of abandonment when each were compared individually.

The study shows that while anti-cancer medicines offer benefits to patients, access to them is difficult due to high rates of cost-sharing. While 73 percent of newly initiated oncolytic patients had a cost-sharing amount of $100 of less, 16 percent required an out-of-pocket cost of greater than $500. The study found that the abandonment rate increased with cost-sharing amounts. Claims with cost-sharing above $500 had the highest abandonment rate – 25 percent – as compared with an abandonment rate of six percent for claims with cost-sharing of $100 or less.

"Our study shows that many cancer patients are abandoning the medicine they need," said Lauren Barnes, vice president, Avalere Health. "With 45.5 percent of Medicare patients in our sample facing cost-sharing greater than $500 for their first a
'/>"/>

SOURCE Avalere Health
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/ctd7zx/europe ) has announced the addition of ... (2014 - 2019)" report to their offering. ... Germany . This is followed by UK and ... Poland are the fastest growing segments. ... the basis of Product (Film Screen, Digital, 3D, Analog Systems, ...
(Date:6/2/2015)... Texas , June 2, 2015 ... report defines and segments the concerned market with ... valued at $261.8 million in 2014, and is ... a CAGR of 19.3% from 2014 to 2019. ... America Mannequin-Based Simulation Market for an analysis of ...
(Date:6/2/2015)... 2015 Intarcia Therapeutics, Inc. today ... its recently announced synthetic royalty / equity convert financing, ... have purchased Convertible Limited Recourse Notes from Intarcia and ... of any future global net sales of ITCA 650 ... also have the option, commencing upon U.S. regulatory approval ...
Breaking Medicine Technology:Europe Mammography Market Report 2014-2019 - Growth, Trends And Forecasts 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3
...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... results on Thursday, April 26, 2012, before the U.S. financial ... 8:30 AM EDT that day. Live audio ... link to the webcast may be accessed from the ,Events ...
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) ... subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to ... DS Healthcare Limited to assist in introducing Clotamin to ... the agreement, DS Healthcare will evaluate the Clotamin formulation ...
Cached Medicine Technology:Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries 2
(Date:6/2/2015)... Erbelli’s Gourmet Pizzeria, Italian Bistro & ... handmade gourmet pizzas and calzones, fresh wraps, submarine sandwiches, ... new, the recipes are not—they have been satisfying the ... of the site is the menu, which is broken ... all the items. You can order directly from the ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 ZOOM+, the ... ZOOM+ Performance Health Insurance, announced today the opening of ... White 57 - a three-in-one complete dental exam, cleaning ... Jr. for kids. Like all ZOOM+ services, ZOOM+Smile can ... “Why shouldn’t the dentist office be as inviting as ...
(Date:6/2/2015)... June 02, 2015 Olive ... opening of Surrey’s first fertility clinic. Surrey ... a diverse, young community, with one of ... , Until now patients from Surrey ... to come into Vancouver or Burnaby for ...
(Date:6/2/2015)... TU-Automotive Detroit is the biggest dedicated B2B connected car ... execs from GM, Chrysler, Mercedes, Ford, TomTom, Zipcar, Nissan ... update on the automotive technology industry and a look ... secure one of the remaining passes. , Justin Parker, ... are 70 sessions looking across the connected car space ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Vancouver, ... by iData Research ( http://www.idataresearch.com ), the bone ... demineralized bone matrices (DBM) over traditional allograft materials. ... incisions and thus an increase in operation time, ... strong market growth in these synthetic materials is ...
Breaking Medicine News(10 mins):Health News:Erbelli’s of Bradenton Launches New Mobile-Friendly Website 2Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:Olive Fertility Centre Opens First Fertility Clinic in Surrey BC 2Health News:The Connected Car’s Biggest Event is Here – TU-Automotive Detroit 2015 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3
... 1 issue of the journal Sleep indicates that ... remain vigilant and attentive deteriorated significantly after losing less than ... study suggests that even moderate reductions in sleep duration can ... the academic performance of children with ADHD. Results of ...
... This release is also available in Chinese on ... Despite the absence of Medicare coverage, hospital use of computed ... the rise, according to a study in the March issue of ... www.jacr.org ). Colorectal cancer is the second leading cause of ...
... dissection, the current standard surgical treatment for localized non-small ... stage cases , according to a study published in the ... (JTO), the official journal of the International Association for the ... is very low in early-stage cancers with a maximum standard ...
... adhesive patches is at the center of an agreement ... arm of Italian pharmaceutical leader Zambon Co., SpA, to ... ways to deliver oral medications directly to a targeted ... sponsored research agreement between Zcube and UCSF, but is ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... fears soaring as quickly as a child,s rapidly rising temperature. ... Pediatrics (AAP) attempts to allay those fears by reminding parents ... against illness, and that lowering a fever may actually prolong ...
... , MONDAY, Feb. 28 (HealthDay News) -- Many American women ... treatment was tied to higher breast cancer risk. A sharp ... after. However, a new study suggests that the 2002-2003 ... continue through 2007. The data suggests that the drop ...
Cached Medicine News:Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 2Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 3Health News:Hospital use of virtual colonoscopy is on the rise, study suggests 2Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:UCSF collaborates with Zcube to develop new ways to deliver drugs 2Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Drop in Breast Cancer Among White Women May Have Stalled 2
... Vessel Dissector has application for use in ... the extraperitoneal spaces such as the retroperitoneal, ... be used in surgical procedures requiring dissection ... harvesting of a quality conduit through a ...
... The Thoratec VAD System includes three ... Drive Console or TLC-II Portable Driver. This ... when the natural heart, with conventional therapy, ... perfuse vital organs. To accomplish support, blood ...
... two distinct polyethylene glycol polymers that combine to ... to chemically bond to each other, as well ... material forms a flexible, watertight seal that remains ... withstand arterial pressure. It is completely resorbed by ...
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
Medicine Products: